If any controlled substance appears in the listed bulk database, please ignore it, as we do not supply or offer controlled substances.
Sacubitril (2R,4R)-Isomer
100% accuracy
of data
24/7 scientific
support
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

766480-48-2Sacubitril (2R,4R)-Isomer

● In Stock

Catalogue No.:VE005968
CAS No.:766480-48-2
Mol. Formula:C24H29NO5
Mol. Weight:411.49 g/mol

Additional information on CAS 766480-48-2

Parent drug

Sacubitril

IUPAC Name

(2R, 4R)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester

Pharmacopoeial Synonyms

N/A

Other synonyms

Sacubitril 4-Epimer

Smiles

O=C(CCC(O)=O)N[C@H](C[C@H](C(OCC)=O)C)CC1=CC=C(C2=CC=CC=C2)C=C1

InChl

InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21-/m1/s1

Description

Sacubitril (2R,4R)-Isomer is a well-characterized reference material that meets stringent regulatory standards set by USP, EMA, JP, and BP. It plays a key role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Sacubitril. It is a neprilysin inhibitor that helps to reduce the risk of cardiovascular death.

References

Kaplinsky, Edgardo. “Sacubitril/Valsartan in Heart Failure: Latest Evidence and Place in Therapy.” Therapeutic Advances in Chronic Disease, vol. 7, no. 6, Oct. 2016, pp. 278–90, https://doi.org/10.1177/2040622316665350. ?

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Products quotation
Name
Url
 
This field is hidden when viewing the form
This field is hidden when viewing the form